Melanomas of skin

Although it is one of the rarer forms of skin cancer, melanoma is responsible for a disproportionate amount of mortality. Its incidence has been increasing over time, and is

...


Read more on Melanomas of skin

 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Cutaneous melanoma

This guideline provides advice at all stages of the patient’s pathway of care, from primary prevention to early recognition, treatment and follow up.

Added 1 year ago

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cutaneous melanoma is the most common type of melanoma, and UV exposure is one of the main risk factors.

Added 4 years ago

Melanoma: assessment and management

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

Added 4 years ago

Search all guidelines for Melanomas of skin
 

Journal articles

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.

Added 1 year ago

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Purpose: To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600–mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination...

Added 1 year ago

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.

Added 1 year ago

Search all journal articles for Melanomas of skin
 

Clinical trials

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

Added 1 year ago

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)

This is a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection.

Added 7 years ago

Search all clinical trials for Melanomas of skin
 

CME

Urgent referrals in dermatology

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Malignant melanoma: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
1
Subscription fee
0

Developments in melanoma treatment

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Melanomas of skin